TY  - JOUR
AU  - Fazekas, Tamás
AU  - Széles, Ádám D
AU  - Teutsch, Brigitta
AU  - Csizmarik, Anita
AU  - Vékony, Bálint
AU  - Kói, Tamás
AU  - Ács, Nándor
AU  - Hegyi, Péter
AU  - Hadaschik, Boris
AU  - Nyirády, Péter
AU  - Szarvas, Tibor
TI  - Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.
JO  - European urology oncology
VL  - 7
IS  - 3
SN  - 2588-9311
CY  - Amsterdam
PB  - Elsevier
M1  - DKFZ-2023-01898
SP  - 365-375
PY  - 2024
N1  - 2024 Jun;7(3):365-375
AB  - Testing for mutations in Breast Cancer Gene 1/2 (BRCA) has emerged as a novel decision-making tool for clinicians. Patients with metastatic castration-resistant prostate cancer (mCRPC) harboring pathogenic BRCA mutations can benefit from poly (ADP-ribose) polymerase inhibitor (PARPi) and platinum treatments, whereas the impact of the mutation on sensitivity to cabazitaxel and prostate-specific membrane antigen (PSMA)-ligand therapy is currently unknown.To assess the efficacy of PARPi, platinum, cabazitaxel, and PSMA-ligand therapies in BRCA-positive mCRPC.Databases were queried in February 2022. We performed data synthesis by using both proportional and individual patient data. For prostate-specific antigen (PSA) response rate (≥50
KW  - Ac-PSMA (Other)
KW  - BRCA (Other)
KW  - Cabazitaxel (Other)
KW  - Carboplatin (Other)
KW  - Cisplatin (Other)
KW  - DNA repair (Other)
KW  - Lu-PSMA (Other)
KW  - Metastatic castration-resistant prostate cancer (Other)
KW  - Niraparib (Other)
KW  - Olaparib (Other)
KW  - Prostate cancer (Other)
KW  - Prostate-specific membrane antigen (Other)
KW  - Rucaparib (Other)
KW  - Talazoparib (Other)
KW  - Taxane (Other)
KW  - Veliparib (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37722977
DO  - DOI:10.1016/j.euo.2023.09.001
UR  - https://inrepo02.dkfz.de/record/282906
ER  -